EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Novel drug development for geographic atrophy

Hiu Ying Enne Leung, Jingfa Zhang, Nishant V Radke, Shaoju Gan, Shiyu Yao, Zhiqiang Wang, Jiaxuan Li, Xiangsheng Liu, Victor Chong, Xie Wang, Weihong Tan, Dennis S C Lam

Asia-Pacific Journal of Ophthalmology · 2026-03 · 15 (2) · 100305

DOI: 10.1016/j.apjo.2026.100305 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Asia-Pacific Journal of Ophthalmology, 2026-03. Verfasst von Hiu Ying Enne Leung und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Primasia International Eye Research Institute (PIERI), School of Medicine, The Chinese University of Hong Kong (Shenzhen), Shenzhen, China. Hauptthemen laut MEDLINE: Geographic Atrophy, Drug Development. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chinese Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Geographic atrophy (GA), the advanced stage of dry age-related macular degeneration, has transitioned from an untreatable condition to a field of active therapeutic development. This review outlines the key molecular pathways driving GA progression, including complement system dysregulation, oxidative stress, and chronic inflammation. A marked important therapeutic milestone with the first FDA approvals of complement inhibitors, Pegcetacoplan and Avacincaptad pegol, demonstrated a modest but statistically significant slowing of lesion growth. However, these anatomic benefits have not consistently translated into meaningful functional visual improvement, underscoring the need for additional therapeutic strategies. Beyond complement, the therapeutic landscape is rapidly expanding to include oral agents, topical therapies, implant-based delivery systems, subcutaneous injections, and device-based approaches targeting oxidative stress, neuroprotection, mitochondrial dysfunction, lipid metabolism and proteostasis. Emerging modalities, including gene therapy, stem cell-based repair, and bioelectronic implants, aim to move beyond disease slowing toward durable retinal restoration. Despite progress, significant unmet needs persist. Key challenges include treatment burden associated with frequent intravitreal injections, safety considerations, and the persistent disconnect between anatomic endpoints and functional outcomes. These underscore the necessity for future treatments that not only alter disease anatomy but also effectively preserve patients' vision and improve their quality of life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Geographic AtrophyDrug DevelopmentHumans

Stichwörter der Autor:innen

Age-related macular degenerationGeographic atrophyMolecular mechanismNovel drug developmentSubchoroidal space injectionTherapeutic pipeline

Autor:innen und Institutionen

  • The Primasia International Eye Research Institute (PIERI), School of Medicine, The Chinese University of Hong Kong (Shenzhen), Shenzhen, China.
  • The Primasia International Eye Research Institute (PIERI), School of Medicine, The Chinese University of Hong Kong (Shenzhen), Shenzhen, China; The C-MER (Shenzhen) Dennis Lam Eye Hospital, Shenzhen, Guangdong, China.
  • The Primasia International Eye Research Institute (PIERI), School of Medicine, The Chinese University of Hong Kong (Shenzhen), Shenzhen, China; Eye Department, C+ Health CKJ (Shenzhen) Hospital, Luohu, Shenzhen, China.
  • The Key Laboratory of Zhejiang Province for Basic and Clinical Application of Functional Nucleic Acids, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, Ch…
  • Institute of Ophthalmology, University College London, London, UK.
  • The Primasia International Eye Research Institute (PIERI), School of Medicine, The Chinese University of Hong Kong (Shenzhen), Shenzhen, China; The C-MER (Shenzhen) Dennis Lam Eye Hospital, Shenzhen, Guangdong, China; E…

Förderung

  • Chinese Academy of Sciences

Zitieren

APA

Leung, H. Y. E., Zhang, J., Radke, N. V., Gan, S., Yao, S., Wang, Z., Li, J., Liu, X., Chong, V., Wang, X., Tan, W., & Lam, D. S. C. (2026). Novel drug development for geographic atrophy. Asia-Pacific Journal of Ophthalmology, 15(2), 100305. https://doi.org/10.1016/j.apjo.2026.100305

Vancouver

Leung HYE, Zhang J, Radke NV, Gan S, Yao S, Wang Z, et al. Novel drug development for geographic atrophy. Asia-Pacific Journal of Ophthalmology. 2026;15(2):100305. doi:10.1016/j.apjo.2026.100305

BibTeX
@article{Leung2026,
  author = {Leung, Hiu Ying Enne and Zhang, Jingfa and Radke, Nishant V and Gan, Shaoju and Yao, Shiyu and Wang, Zhiqiang and Li, Jiaxuan and Liu, Xiangsheng and Chong, Victor and Wang, Xie and Tan, Weihong and Lam, Dennis S C},
  title = {Novel drug development for geographic atrophy},
  journal = {Asia-Pacific Journal of Ophthalmology},
  year = {2026},
  volume = {15},
  number = {2},
  pages = {100305},
  doi = {10.1016/j.apjo.2026.100305}
}
Kostenlos starten →